Justus-Liebig-Universität Gießen

Futó vizsgálatok

• Még nem toboroz

  A Study of Ivonescimab Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants with Unresectable Stage III NSCLC

  2026-526300-67-00· 3. fázis· Summit Therapeutics Inc.· Forrás

• Még nem toboroz

  Study of safety and tolerability following administration of metformin in patients with idiopathic pulmonary fibrosis (IPF)

  2025-523341-10-00· 2. fázis· Philipps-Universitaet Marburg· Forrás

• Még nem toboroz

  PD-1 Blockade Alone Versus in Combination With Chemotherapy as First Line Therapy in Females With Advanced NSCLC & PD-L1 Expression ≥50%

  NCT07877584· 3. fázis· German Cancer Research Center· Forrás

• Még nem toboroz

  Investigation of breathable surfactant agent in patients with idiopathic lung fibrosis

  2023-508544-22-00· 2. fázis· Philipps-Universitaet Marburg· Forrás

• Még nem toboroz

  Remote Monitoring and Optimization of Heart Failure Therapy

  NCT07622472· Zoll Medical Corporation· Forrás

• Toboroz

  A Phase III, Open-Label, Randomised, Multicentre, Global Study of Adjuvant Datopotamab Deruxtecan in Combination With Rilvegostomig in Participants With High-risk Muscle Invasive Urothelial Carcinoma.

  2025-525030-57-00· 3. fázis· AstraZeneca AB· Forrás

• Toboroz

  Efanesoctocog alfa treatment in patients with congenital hemophilia A suffering from inflammation of joint lining

  2025-523896-44-00· 3. fázis· GWT-Tud GmbH· Forrás

• Toboroz

  Study of Izalontamab Brengitecan (BMS-986507) in Combination With Osimertinib Versus Osimertinib Monotherapy or Osimertinib in Combination With Platinum-based Chemotherapy for EGFRmt Non-small Cell Lung Cancer (IZABRIGHT-Lung02)

  NCT07680790· 3. fázis· Bristol-Myers Squibb· Forrás

• Toboroz

  A Phase IIb Study to Evaluate AZD8965 in Participants with Idiopathic Pulmonary Fibrosis (IPF)

  2025-525016-41-00· 2. fázis· AstraZeneca AB· Forrás

• Toboroz

  A Study Evaluating Ficerafusp Alfa (BCA101) QW in Combination With Pembrolizumab vs Alternative Ficerafusp Alfa Dosing in 1L R or M HNSCC

  NCT07807163· 2. fázis· Bicara Therapeutics· Forrás

• Még nem toboroz

  AIEOP-BFM ALL 2025 - International collaborative treatment protocol for children and adolescents with acute lymphoblastic leukemia

  2025-522190-11-01· 3. fázis· Universitaetsklinikum Schleswig-Holstein AöR· Forrás

• Toboroz

  A Study to Find an Efficacious and Safe Dose of CHF10067 (Zampilimab) in Participants With Idiopathic Pulmonary Fibrosis

  NCT07516951· 2. fázis· Chiesi Farmaceutici S.p.A.· Forrás

• Még nem toboroz

  GMMG-HD11/DSMM XXI/64007957MMY3010

  NCT07671287· 3. fázis· University of Heidelberg Medical Center· Forrás

• Toboroz

  A Clinical Trial of Calderasib (MK-1084) and Durvalumab in People With Non-Small Cell Lung Cancer (MK-1084-015/KANDLELIT-015)

  NCT07554339· 3. fázis· Merck Sharp & Dohme LLC· Forrás

• Toboroz

  PREFer

  NCT06916416· 2. fázis· University Of Cologne· Forrás

• Toboroz

  Study of REGN13335 in Adult Participants With Pulmonary Arterial Hypertension (PAH)

  NCT07318597· 2. fázis· Regeneron Pharmaceuticals· Forrás

• Toboroz

  A Clinical Study of MK-1045 in People With Non-Hodgkin Lymphoma (MK-1045-008)

  NCT07519772· 1/2. fázis· Merck Sharp & Dohme LLC· Forrás

• Toboroz

  An Adaptive Program of IKT-001 in Pulmonary Arterial Hypertension (PAH)

  NCT07365332· 3. fázis· Inhibikase Therapeutics· Forrás

• Toboroz

  MK-3475A±Calderasib (MK-1084) in Completely Resected Stage IIA-IIIB (N2) KRAS G12Cm NSCLC (MK-1084-013)

  NCT07431827· 3. fázis· Merck Sharp & Dohme LLC· Forrás

• Toboroz

  AURA-IPF: A Randomized Phase 2 Study to Evaluate the Safety and Efficacy of AP02 (Nintedanib Solution) in IPF

  NCT07194382· 2. fázis· Avalyn Pharma Inc.· Forrás

• Toboroz

  Study to Assess the Efficacy and Safety of Rina-S in Participants With Non-small Cell Lung Cancer

  NCT07288177· 2. fázis· Genmab· Forrás

• Toboroz

  Non-inferiority Study of Frexalimab Subcutaneous Administration Compared to Intravenous Administration in Adult Participants With Multiple Sclerosis

  NCT07325292· 3. fázis· Sanofi· Forrás

• Toboroz

  Nivolumab in combination with cisplatin and 5-fluorouracil as induction therapy in children and adults with EBV-positive nasopharyngeal carcinoma

  2022-500676-59-00· 2. fázis· GPOH gGmbH· Forrás

• Toboroz

  A Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Telisotuzumab Adizutecan, Monotherapy or in Combination With Osimertinib, Compared to Standard of Care in Adult Participants With Locally Advanced or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer

  NCT07155187· 2/3. fázis· AbbVie· Forrás

• Toboroz

  Study on chemotherapy and experimental drugs in patients with Philadelphia Chromosome positive and ABL-class Philadelphia Chromosome-Like B-cell Acute Lymphoblastic Leukemia

  2025-520982-39-00· 3. fázis· Universita Degli Studi Di Milano Bicocca· Forrás

• Toboroz

  A Study of Amivantamab in Addition to Standard of Care Agents (SOC) Compared With SOC Alone in Participants With Recurrent/Metastatic Head and Neck Cancer

  NCT07276399· 3. fázis· Janssen Research & Development, LLC· Forrás

• Toboroz

  A Study to Evaluate the Optimal Dose, Adverse Events and Change in Disease Activity of Intravenous ABBV-706 in Combination With Atezolizumab Versus Standard of Care as First-Line Treatment in Adult Participants With Previously Untreated Extensive Stage Small Cell Lung Cancer

  NCT07155174· 2. fázis· AbbVie· Forrás

• Toboroz

  Phase II Study Evaluating Ivosidenib Maintenance After SOC Adjuvant Chemotherapy in Curative mIDH1 Cholangiocarcinoma

  NCT07260175· 2. fázis· Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest· Forrás

• Toboroz

  Phase 2 Study of ADX-038 in Participants With Geographic Atrophy

  NCT06990269· 2. fázis· ADARx Pharmaceuticals, Inc.· Forrás

• Toboroz

  Early Treatment of Atrial Fibrillation for Stroke Prevention Trial in Acute STROKE

  NCT05293080· 3. fázis· Universitätsklinikum Hamburg-Eppendorf· Forrás

• Toboroz

  Re-Radiochemotherapy and Pembrolizumab vs. Immuno(Chemo)Therapy for Locoregionally Recurrent PD-L1 Positive (CPS≥1) HNSCC

  NCT07026474· 3. fázis· Universität des Saarlandes· Forrás

• Toboroz

  Study of Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy in First-line HER2 Overexpressing Non-small Cell Lung Cancer

  NCT06899126· 3. fázis· Daiichi Sankyo· Forrás

• Toboroz

  Study to Evaluate the Efficacy and Safety of Oral Rilzabrutinib in Adults With Immune Thrombocytopenia (ITP) Who Failed First-line Treatment

  NCT07007962· 3. fázis· Sanofi· Forrás

• Toboroz

  A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)

  NCT07144280· 3. fázis· Pfizer· Forrás

• Toboroz

  A Study to Learn About the Treatment LTP001 in Healthy Participants (Part A) and in Participants With PAH (Part B)

  2024-513613-12-00· 1/2. fázis· Novartis Pharma AG· Forrás

• Toboroz

  Osimertinib plus chemotherapy as 1st line therapy in stage IV NSCLC patients with atypical EGFR mutations (AIO-TRK/YMO-0324)

  2024-516790-78-00· 2. fázis· Universitat Heidelberg· Forrás

• Toboroz

  Phase 3 Study of Taletrectinib vs Placebo as an Adjuvant Therapy in ROS1 Positive NSCLC (TRUST-IV)

  NCT07154706· 3. fázis· Nuvation Bio Inc.· Forrás

• Toboroz

  A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation

  NCT06952803· 3. fázis· AstraZeneca· Forrás

• Toboroz

  This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.

  NCT06758401· 3. fázis· Pfizer· Forrás

• Toboroz

  DB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors

  NCT06953089· 2. fázis· DualityBio Inc.· Forrás

• Toboroz

  A Study of Patritumab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors (MK-9999-01C/LIGHTBEAM-U01)

  NCT06941272· 1/2. fázis· Merck Sharp & Dohme LLC· Forrás

• Toboroz

  Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)

  NCT06881784· 3. fázis· Revolution Medicines, Inc.· Forrás

• Toboroz

  A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)

  NCT06875310· 3. fázis· Mirati Therapeutics Inc.· Forrás

• Toboroz

  Immunochemotherapy, Surgery or Chemoradiation, and Durvalumab for Stage IIIA/B NSCLC

  NCT06810609· 2. fázis· University Hospital, Bonn· Forrás

• Toboroz

  Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1

  NCT06767514· 3. fázis· Summit Therapeutics· Forrás

• Fut, nem toboroz

  Study to Assess the Efficacy of Rina-S Compared to Treatment of Investigator's Choice in Participants With Platinum Resistant Ovarian Cancer

  NCT06619236· 3. fázis· Genmab· Forrás

• Toboroz

  A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Non-Squamous NSCLC

  NCT06627647· 3. fázis· AstraZeneca· Forrás

• Toboroz

  A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)

  NCT06692738· 3. fázis· AstraZeneca· Forrás

• Toboroz

  A phase 3 trial comparing a therapeutic cancer vaccine OSE2101 to chemotherapy docetaxel in patients with metastatic Non-Small Cell Lung Cancer (NSCLC) after immunotherapy failure.

  2023-509340-10-00· 3. fázis· OSE Immunotherapeutics· Forrás

• Toboroz

  A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)

  NCT06623422· 3. fázis· Merck Sharp & Dohme LLC· Forrás

Showing 50 of 113.

Egyszerre toboroz

Hány vizsgálat toboroz itt egyszerre ugyanarra az indikációra. Darabszám, nem értékelés.

• Tüdőrák25 toboroz
• Gyermekkori daganatok13 toboroz
• Fej-nyaki daganatok6 toboroz
• Akut limfoid leukémia (ALL)5 toboroz
• Idiopátiás tüdőfibrózis5 toboroz
• Hodgkin-limfóma3 toboroz
• Magas vérnyomás3 toboroz
• Petefészekrák3 toboroz
• Pulmonális artériás hipertónia3 toboroz
• Szarkóma3 toboroz
• Diffúz nagy B-sejtes limfóma (DLBCL)2 toboroz
• Follikuláris limfóma2 toboroz
• Hemofília2 toboroz
• Máj- és epeúti rák2 toboroz
• Melanóma2 toboroz
• Akut mieloid leukémia (AML)1 toboroz
• Burkitt lymphoma1 toboroz
• Cisztás fibrózis1 toboroz
• Colitis ulcerosa1 toboroz
• Crohn-betegség1 toboroz
• Hólyagrák1 toboroz
• Időskori makuladegeneráció1 toboroz
• Immune thrombocytopenia (ITP)1 toboroz
• Koszorúér-betegség1 toboroz
• Méhnyakrák1 toboroz
• Mielodiszplasztikus szindróma (MDS)1 toboroz
• Mielóma multiplex1 toboroz
• Neuroblasztóma1 toboroz
• Pitvarfibrilláció1 toboroz
• Pompe-betegség1 toboroz
• Prosztatarák1 toboroz
• Sclerosis multiplex (SM)1 toboroz
• Spinális izomatrófia (SMA)1 toboroz
• Stroke (szélütés)1 toboroz
• Szívelégtelenség1 toboroz

Lezárt vizsgálatok

• Lezárult

  Integrated PK/efficacy, safety, and immunogenicity study to demonstrate similarity of JPB898, a proposed biosimilar to nivolumab, to Opdivo® in combination with Yervoy®

  NCT06587451· 3. fázis· H e x a l AG· Forrás

• Lezárult

  Multispectral Optoacustic Imaging in Patients With Myositis

  NCT06966739· University of Giessen· Forrás

• Fut, nem toboroz

  A Study to Compare ABP 234 and Keytruda® (Pembrolizumab) in Participants With Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer

  NCT06311721· 3. fázis· Amgen· Forrás

• Lezárult

  A randomized, double-blind, dose-ranging, placebo-controlled study to evaluate the efficacy and safety of PLN-74809 (bexotegrast) for the treatment of idiopathic pulmonary fibrosis (BEACON-IPF)

  2023-506185-31-00· 2/3. fázis· Pliant Therapeutics Inc.· Forrás

• Lezárult

  A Study designed to evaluate the efficacy and safety of tiragolumab plus atezolizumab compared with placebo plus atezolizumab administered in participants with PD-L1 ≥ 1% TC Stage IIB, IIIA, or select IIIB (T3N2 only) NSCLC following resection and adjuvant platinum-based chemotherapy

  2023-506696-10-00· 3. fázis· F. Hoffmann-La Roche AG· Forrás

• Lezárult

  A Phase 3 Double-masked, Randomized, Multicenter Study of the Efficacy and Safety of OCS-01 Eye Drops in Subjects With Diabetic Macular Edema

  2023-507207-66-00· 3. fázis· Oculis Operations S.a.r.l.· Forrás

• Fut, nem toboroz

  Iberdomide vs. Iberdomide Plus Isatuximab Maintenance Therapy Post ASCT in Newly Diagnosed Multiple Myeloma

  NCT06216158· 3. fázis· University of Heidelberg Medical Center· Forrás

• Lezárult

  A Study to Investigate the Safety and Efficacy of KER-012 in Combination With Background Therapy in Adult Participants With Pulmonary Arterial Hypertension (PAH) (TROPOS).

  NCT05975905· 2. fázis· Keros Therapeutics Inc.· Forrás

• Fut, nem toboroz

  DAREONᵀᴹ-8: A Study to Test How Well Different Doses of BI 764532 in Addition to Standard of Care Are Tolerated by People With Advanced Small Cell Lung Cancer

  NCT06077500· 1. fázis· Boehringer Ingelheim· Forrás

• Lezárult

  Efficacy and Safety of Seralutinib in Adult Subjects With PAH (PROSERA)

  NCT05934526· 3. fázis· GB002, Inc.· Forrás

• Fut, nem toboroz

  A Study of JNJ-86974680 in Participants With Advanced Non-small Cell Lung Cancer

  NCT06116786· 1. fázis· Johnson & Johnson Enterprise Innovation Inc.· Forrás

• Lezárult

  Mavacamten Impact on Myocardial Structure in Obstructive Hypertrophic Cardiomyopathy

  2022-502316-36-00· 4. fázis· Myokardia Inc.· Forrás

• Lezárult

  Tuvusertib (M1774) in Combination With Cemiplimab in Participants With Non-Squamous NSCLC (DDRiver NSCLC 322)

  NCT05882734· 1/2. fázis· EMD Serono Research & Development Institute, Inc.· Forrás

• Lezárult

  A Phase 2b, Randomized, Double-blind Study of Redasemtide (S-005151) in Adult Participants With Acute Ischemic Stroke

  NCT05953480· 2. fázis· Shionogi· Forrás

• Lezárult

  A 24-month study evaluating physical activity and joint health in patients 12 years and older, with severe haemophilia A treated once weekly with efanesoctocog alfa.

  2022-500275-31-00· 3. fázis· Swedish Orphan Biovitrum AB (publ)· Forrás

• Lezárult

  Inhaled Imatinib Pulmonary Arterial Hypertension Clinical Trial – Follow Up Long Term Extension (IMPAHCT-FUL)

  NCT05557942· 3. fázis· Aerovate Therapeutics Inc.· Forrás

• Fut, nem toboroz

  A Trial to Learn How the Cancer Vaccine BNT116 in Combination With Cemiplimab Works and How Safe the Combination is in Adults With Advanced Non-small Cell Lung Cancer (EMPOWERVAX Lung 1)

  NCT05557591· 2. fázis· Regeneron Pharmaceuticals· Forrás

• Lezárult

  A Study to Evaluate Intravitreal JNJ-81201887 (AAVCAGsCD59) Compared to Sham Procedure for the Treatment of Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)

  NCT05811351· 2. fázis· Janssen Research & Development, LLC· Forrás

• Fut, nem toboroz

  A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack- LIBREXIA-STROKE

  NCT05702034· 3. fázis· Janssen Research & Development, LLC· Forrás

• Lezárult

  A Study to Test Asundexian for Preventing a Stroke Caused by a Clot in Participants After an Acute Ischemic Stroke or After a High-risk Transient Ischemic Attack, a So-called Mini Stroke

  NCT05686070· 3. fázis· Bayer· Forrás

• Fut, nem toboroz

  Study to Evaluate Elexacaftor/Tezacaftor/Ivacaftor (ELX/TEZ/IVA) Long-term Safety and Efficacy in Subjects Without F508del

  NCT05331183· 3. fázis· Vertex Pharmaceuticals Incorporated· Forrás

• Fut, nem toboroz

  Study of the Adverse Events and Change in Disease State of Pediatric Participants (and Young Adults Between the Ages of 18-25) With Relapsed/Refractory Aggressive Mature B-cell Neoplasms Receiving Subcutaneous (SC) Injections of Epcoritamab

  NCT05206357· 1. fázis· Genmab· Forrás

• Fut, nem toboroz

  Study of Inupadenant (EOS100850) With Chemotherapy as Second Line Treatment for Nonsquamous Non-small Cell Lung Cancer

  NCT05403385· 2. fázis· iTeos Therapeutics· Forrás

• Lezárult

  Inhaled Imatinib Pulmonary Arterial Hypertension Clinical Trial (IMPAHCT) or A Phase 2b/3, Randomized, Controlled, 24-week Dose Ranging and Confirmatory Study of AV-101 in Patients with PAH

  NCT05036135· 2/3. fázis· Aerovate Therapeutics Inc.· Forrás

• Felfüggesztve

  Treating Nightmares in Posttraumatic Stress Disorder With Clonidine and Doxazosin

  NCT05360953· 2. fázis· Charite University, Berlin, Germany· Forrás

• Lezárult

  A Phase 3 Study of Sotatercept in Newly Diagnosed Intermediate- and High-risk Pulmonary Arterial Hypertension (PAH) Patients.

  NCT04811092· 3. fázis· Acceleron Pharma Inc.· Forrás

• Lezárult

  ​Study of Pembrolizumab/Vibostolimab Coformulation (MK-7684A) in Combination with Chemotherapy Versus Pembrolizumab Plus Chemotherapy as First Line Treatment for Participants with Metastatic Non-Small Cell Lung Cancer (MK-7684A-007/KEYVIBE-007)​

  NCT05226598· 3. fázis· Merck Sharp & Dohme LLC· Forrás

• Lezárult

  A Study of Sotatercept for the Treatment of Cpc-PH Due to HFpEF (MK-7962-007/A011-16)

  NCT04945460· 2. fázis· Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA· Forrás

• Lezárult

  A Study of Sotatercept in Participants With PAH WHO FC III or FC IV at High Risk of Mortality (MK-7962-006/ZENITH)

  NCT04896008· 3. fázis· Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA· Forrás

• Lezárult

  Safety and Efficacy Study of GEN1046 as a Single Agent or in Combination With Pembrolizumab for Treatment of Recurrent (Non-small Cell) Lung Cancer

  NCT05117242· 2. fázis· Genmab A/S· Forrás

• Leállították

  A Study Evaluating Safety, PK, and Efficacy of Tafasitamab and Parsaclisib in Participants With Relapsed/Refractory Non Hodgkin Lymphoma (R/R NHL) or Chronic Lymphocytic Leukemia (CLL)

  NCT04809467· 1/2. fázis· Incyte Corporation· Forrás

• Lezárult

  A Long-term Follow-up Study of Sotatercept for PAH Treatment

  NCT04796337· 3. fázis· Acceleron Pharma Inc.· Forrás

• Lezárult

  A Phase 3 Study to Compare the Efficacy and Safety of HLX04-O with Ranibizumab in Subjects with WAMD

  NCT04740671· 3. fázis· Shanghai Henlius Biotech· Forrás

• Toboroz

  Special Care Patterns for Elderly HNSCC Patients Undergoing Radiotherapy

  NCT05337631· University Hospital Freiburg· Forrás

• Lezárult

  A Phase 3, Randomized, Double-Blind Study of Ociperlimab, an Anti-TIGIT Antibody, in Combination With Tislelizumab Compared to Pembrolizumab in Patients With Previously Untreated, PD-L1-Selected, and Locally Advanced, Unresectable, or Metastatic Non-Small Cell Lung Cancer

  NCT04746924· 3. fázis· Beigene Ltd.· Forrás

• Lezárult

  Right Atrial Fibrosis in Pulmonary Hypertension

  NCT04663230· University of Giessen· Forrás

• Toboroz

  RESTORE - Study of AGN1 LOEP to Prevent Secondary Hip Fractures

  NCT04796350· AgNovos Healthcare, LLC· Forrás

• Lezárult

  A Study to Learn About the Long-Term Safety of Higher Doses of Nusinersen (BIIB058) Given as Injections to Participants With Spinal Muscular Atrophy (SMA) Who Took Part in an Earlier Nusinersen Trial (ONWARD)

  NCT04729907· 3. fázis· Biogen· Forrás

• Fut, nem toboroz

  Study of DS-1062a Versus Docetaxel in Previously Treated Advanced or Metastatic Non-small Cell Lung Cancer With or Without Actionable Genomic Alterations (TROPION-LUNG01)

  NCT04656652· 3. fázis· Daiichi Sankyo· Forrás

• Lezárult

  Exercise Hemodynamic, Right Ventricular Coupling and Echocardiography in Pulmonary Hypertension

  NCT04663217· University of Giessen· Forrás

• Lezárult

  Advancing Brigatinib Properties in ALK+ NSCLC Patients by Deep Phenotyping

  NCT04318938· 2. fázis· Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest· Forrás

• Fut, nem toboroz

  ZIP Study-OL Study of Safety, PK, Efficacy, PD, Immunogenicity of ATB200/AT2221 in Pediatrics Aged 0 to < 18 y.o. w/LOPD

  NCT03911505· 3. fázis· Amicus Therapeutics· Forrás

• Lezárult

  The Late Presenter Treatment Optimisation Study

  NCT03696160· 3. fázis· NEAT ID Foundation· Forrás

• Lezárult

  A Study of INCB050465 in Relapsed or Refractory Mantle Cell Lymphoma Previously Treated With or Without a Bruton's Tyrosine Kinase (BTK) Inhibitor

  NCT03235544· 2. fázis· Incyte Corporation· Forrás

• Lezárult

  HD21

  NCT02661503· 3. fázis· University Of Cologne· Forrás

• Lezárult

  Second International Inter-Group Study for Classical Hodgkin Lymphoma in Children and Adolescents

  NCT02684708· 3. fázis· University of Giessen· Forrás

Betegségek

Betegségek, amelyekről az intézmény publikál vagy amelyekre vizsgálatot futtat.

• Pulmonális artériás hipertónia47 munka · 15 vizsgálat
• Szisztémás szklerózis (szkleroderma)24 munka · 0 vizsgálat
• Idiopátiás tüdőfibrózis21 munka · 7 vizsgálat
• Hodgkin-limfóma20 munka · 6 vizsgálat
• Aortic stenosis19 munka · 1 vizsgálat
• Cisztás fibrózis17 munka · 2 vizsgálat
• Myocarditis10 munka · 0 vizsgálat
• Immune thrombocytopenia (ITP)6 munka · 2 vizsgálat
• Pompe-betegség5 munka · 2 vizsgálat
• Restless legs syndrome3 munka · 0 vizsgálat
• Eosinophilic oesophagitis3 munka · 0 vizsgálat